breast cancer
Conditions
Interventions
Experimental group:Eribulin mesylate, 1.4 mg /m2, day 1 and day 8
Carboplatin, AUC6, day 1
Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1
Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1
21 days per cycle, a total of 6 cycles
Sponsors
Sichuan Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Newly treated female patients >=18 years old and =1.5×10^9/L; Platelet count (PLT) >=100×10^9/L; Red blood Protein (Hb) =90 g/L; Blood biochemistry: total bilirubin (TBIL) =55%; For female patients who are not menopausal or have not been surgically sterilized: arrive after the last dose during treatment and study therapy within six months, agree to abstain from sex or use an effective contraceptive method. Participate in this study voluntarily, sign informed consent, have good compliance and willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: Stage IV breast cancer; Other specific types of breast cancer; Antitumor therapy or radiation therapy for any malignancy within the previous 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma; Also receiving antitumor therapy in other clinical trials; Had major non-breast cancer related surgery within 4 weeks prior to randomization, or had not yet undergone such surgery Complete recovery in progress. Serious cardiovascular and cerebrovascular diseases or discomfort, including but not limited to the following diseases: History of heart failure or systolic dysfunction (LVEF 180 mmHg and/or diastolic blood pressure > 100 mmHg) Known allergic history of drug components of the program; A history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency conditions, or have a history of organ transplantation; Pregnant and lactating women, fertile women with a positive baseline pregnancy test, or patients in Patients of childbearing age who were unwilling to use effective contraception throughout the trial period; The patient has a serious concomitant disease or other comorbiditis that would interfere with planned treatment, or any other circumstances where the researcher deems the patient unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pCR rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Quality of Life; | — |
Countries
China
Contacts
Public ContactJunjie Li
Sichuan Cancer Hospital
Outcome results
None listed